http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2553133-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9f098cc4b7d0e25be702a2281fce418b |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-217 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1808 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-195 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2006 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2013 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-191 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-193 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N37-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate | 2005-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_13559a53478b411192b023e51f0e604b |
| publicationDate | 2015-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2553133-T3 |
| titleOfInvention | Method of modifying the proportion of CD4 / CD8 and mononuclear cell infiltrate in a tumor |
| abstract | A therapeutically active amount of a serum-free and mitogen-free mixture of cytokines for use in a method of cancer presensitization by modifying the CD4 / CD8 ratio in a head and neck tumor, said mixture of cytokines being administered serum-free and mitogen-free five times a week for a period of three weeks in an amount of 800 IU, IU representing international units for interleukin 2 given in the first international standard of the World Health Organization for IL- 2 human, 86/504, in which 400 IU of said 800 IU of serum-free and mitogen-free cytokine mixture are injected peritumorally into four different zones located around a tumor mass, so that 100 IU are injected into each one of the four zones and 400 IU / ml are injected perilymphatically ipsilateral to the tumor mass; and wherein said mixture of serum-free and mitogen-free cytokines is composed of the following specific proportions of cytokine selected from the group of IL-1b, TNF-a, IFN-g and GM-CSF with respect to interleukin 2 (IL -2): IL-1b with respect to IL-2 at a ratio range of 0.4 to 1.5; TNF-a with respect to IL-2 at a ratio range of 3.2 to 11.3; IFN-g with respect to IL-2 at a ratio range of 1.5 to 10.9; and GM-CSF with respect to IL-2 at a ratio range of 2.2 to 4.8. |
| priorityDate | 2004-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 267.